The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
Open accessAbstract
The main protease (M pro ) of SARS-CoV-2 is a validated antiviral drug target. Several M pro inhibitors have been reported with potent enzymatic inhibition and cellular antiviral activity, including GC376, boceprevir, calpain inhibitors II, and XII, with each containing a reactive warhead that covalently modifies the catalytic Cys145. Coupling structure-based drug design with the one-pot Ugi four-component reaction, we discovered one of the most potent noncovalent inhibitors, 23R ( Jun8-76-3A ) that is structurally distinct from the canonical M pro inhibitor GC376 . Significantly, 23R is highly selective compared with covalent inhibitors such as GC376, especially toward host proteases. The cocrystal structure of SARS-CoV-2 M pro with 23R revealed a previously unexplored binding site located in between the S2 and S4 pockets. Overall, this study discovered 23R, one of the most potent and selective noncovalent SARS-CoV-2 M pro inhibitors reported to date, and a novel binding pocket in M pro that can be explored for inhibitor design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marty, M. T., Baldwin, A. J., Marklund, E. G., Hochberg, G. K. A., Benesch, J. L. P., & Robinson, C. V. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00140 · Cited by 1,000
Self-citationDrug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
Ghosh, A. K., Brindisi, M., Shahabi, D., Chapman, M. E., & Mesecar, A. D. (2020) · ChemMedChem · doi:10.1002/cmdc.202000223 · Cited by 306
Cited by
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
Hu, Y., Lewandowski, E. M., Tan, H., Zhang, X., Morgan, R. T., Zhang, X., Jacobs, L. M. C., Butler, S. G., Gongora, M. V., Choy, J., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00538 · Cited by 333
Self-citationMa, C., Tan, H., Choza, J., Wang, Y., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.026 · Cited by 86
Self-citation
Metadata
- Authors
- Kitamura, N., Sacco, M. D., Ma, C., Hu, Y., Townsend, J. A., Meng, X., Zhang, F., Zhang, X., Ba, M., Szeto, T., Kukuljac, A., Marty, M. T., Schultz, D., Cherry, S., Xiang, Y., Chen, Y., & Wang, J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-04-23
- Volume
- 65
- Issue
- 4
- Pages
- 2848-2865
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3152703278
- Cited by
- 164
- References
- 2
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors. https://app.cochat.ai/papers/10.1021/acs.jmedchem.1c00509
- The paper
- Kitamura, N., Sacco, M. D., Ma, C., Hu, Y., Townsend, J. A., Meng, X., Zhang, F., Zhang, X., Ba, M., Szeto, T., Kukuljac, A., Marty, M. T., Schultz, D., Cherry, S., Xiang, Y., Chen, Y., & Wang, J. (2022). Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c00509
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.